Bottom cards (Which this is) does not render the title text, so what you put here doesn't matter.

The DDRB report: What impact will it have on doctors' pay packets?

Doctor fatigue: Are there lessons to be learnt from the aviation industry?

From blood clots to rare cancers, a plastic surgeon explains the risks to consider before going under the knife – or the needle

Post-sepsis syndrome: when the body recovers but the brain doesn't

Analysis and Opinion

# The news that impacts UK doctors

The National Institute for Health and Care Excellence has recommended osimertinib, also known as Tagrisso and made by AstraZeneca, in [final draft guidance](https://www.nice.org.uk/guidance/indevelopment/gid-ta11369/documents) as an additional treatment for people with [EGFR mutation-positive non-small-cell lung cancer (NSCLC)](https://www.egfrpositive.org.uk/what-is-egfr) after surgery.

NICE approves targeted treatment for non-small-cell lung cancer

Log in or join for free to read more

You might also like